KBC in terms of a new CEO and BOD I'd prefer a situation more like Montreal/Boston based Repare Therapeutics.

1. Founded by 2 academics in 2016.
2. Brought in heavyweight biotech financing expert Llyod Segal around 2018 or 2019.
3. Segal rallied other biotech financial types for early funding.
4. NASDAQ IPO announced June 18, 2020 or there abouts with no drugs at clinical stage.
5. IPO at $20USD fully sold and share price moved up to high $20s or more.
6. Current share price =$13.67USD.
7. Cash on hand = $282 million USD. 
8. Debt = $6.6 million USD.
9. Current drugs only at ph1/2b trials, discovery and IND phases.

I believe Zenith has at least as many if not more trials in progress and is showing positive results. ZE also has a number of high profile BP partners involved in their research. This also includes the NCI and NIH if I recall correctly. These are remarkable science & business achievements (thanks Dr Lakhotia) not being recognized in terms of shareholder value because management does not have either the vision or skills (Dr Lakhotia being the exception) to provide the kind of financing that this science deserves. It is travisty.

And now, they will proceed for another year with a mediocre BOD and an incompetent CEO.

The talent is out there and somebody, the ZCC CEO, is afraid to tap into amazing, value creating resources. It is shamefull.

I'd be happy with a $20USD NASDAQ IPO in December if ZCC had a new CEO in place.

It will be interesting to see what "Mr Very Excited" has to discuss this year.

JMO

Frustrated Toinv